News

Beacon Therapeutics Announces EURETINA 2025 Presentations on 9+-Month Phase 2 DAWN and 36-Month Phase 2 SKYLINE Trial Data for laru-zova in Patients with X-linked Retinitis ...

Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...
Newseria BIZNES4h

Pigments Market to Reach USD 58.9 Billion by 2035, Driven by Demand from Construction and Automotive Sectors

WILMINGTON, DE, UNITED STATES, August 21, 2025 /EINPresswire.com/ -- The global pigments market is witnessing significant ...